PDS Biotech gains on positive interim cancer trial data for therapy combination

PDS Biotechnology

26/05/2023 13:44

(Updates)
    ** Shares of cancer immunotherapy developer PDS
Biotechnology Corp  PDSB.O  extend premarket gains to rise about
~29% at $8.7 
        ** Stock among top 5 pct. gainers across U.S. stock
exchanges premarket
  
    ** Late Thursday, co reported positive interim data from
mid-stage trial testing efficacy of its lead candidate PDS0101
in combination with Merck & Co Inc's  MRK.N  therapy Keytruda
    ** Co adds the combination treatment showed an estimated
12-month survival rate of 87% in patients with a type of head
and neck cancer
    ** Also demonstrated a disease control rate (disease
stabilization or tumor shrinkage) of 70.6% and a
progression-free survival of 10.4 months
    ** Co, however, adds that the combination treatment has not
yet met median overall survival
    ** 8% of patients experienced a Grade 3 treatment-related
adverse event without more serious Grade 4 or 5 events - company
    ** Up to Thursday's close, stock down 49.1% YTD

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))